The U.S. Food and Drug Administration (FDA) accepted and allowed a New Drug Application (NDA) submitted by two pharma companies for their collaborative compound revefenacin, a bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) in adults. The two pharmaceutical companies are aiming to develop and commercialize revefenacin as the first once-daily long-acting muscarinic antagonist (LAMA) nebulizer for COPD and other respiratory illnesses. Revefenacin belongs to the LAMA class of compounds that inhibit neurotransmitter receptors in the muscle cells and mucous glands of the lungs’ bronchia.
LAMAs are used as maintenance bronchodilators in COPD, helping to keep narrowed airways open. The FDA has authorized powder and liquid versions of LAMAs, but never a mist version that could be used as a nebulizer. If approved, revefenacin will be the first once-a-day mist…
